BMS/Pfizer Eliquis under FDA review to prevent post-surgery DVT
This article was originally published in Scrip
The FDA has accepted for review the supplemental new drug application (sNDA) for Pfizer's and Bristol-Myers Squibb's Eliquis (apixaban) to prevent deep vein thrombosis (DVT) – a blood clot in a vein, usually in the leg, that partially or totally blocks the flow of blood, which may lead to pulmonary embolism (PE) – in adults who have had hip or knee replacement surgery.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.